Jamshidi H - Search Results

1

Umbelliprenin is Potentially Toxic Against the HT29, CT26, MCF-7, 4T1, A172, and GL26 Cell Lines, Potentially Harmful Against Bone Marrow-Derived Stem Cells, and Non-Toxic Against Peripheral Blood Mononuclear Cells.

Rashidi M, Ziai SA, Moini Zanjani T, Khalilnezhad A, Jamshidi H, Amani D. Rashidi M, et al. Among authors: jamshidi h. Iran Red Crescent Med J. 2016 May 14;18(7):e35167. doi: 10.5812/ircmj.35167. eCollection 2016 Jul. Iran Red Crescent Med J. 2016. PMID: 27703798 Free PMC article.

2

Evaluating cytotoxic effect of nanoliposomes encapsulated with umbelliprenin on 4T1 cell line.

Rashidi M, Ahmadzadeh A, Ziai SA, Narenji M, Jamshidi H. Rashidi M, et al. Among authors: jamshidi h. In Vitro Cell Dev Biol Anim. 2017 Jan;53(1):7-11. doi: 10.1007/s11626-016-0080-7. Epub 2016 Sep 12. In Vitro Cell Dev Biol Anim. 2017. PMID: 27620062

3

Umbelliprenin shows antitumor, antiangiogenesis, antimetastatic, anti-inflammatory, and immunostimulatory activities in 4T1 tumor-bearing Balb/c mice.

Rashidi M, Khalilnezhad A, Amani D, Jamshidi H, Muhammadnejad A, Bazi A, Ziai SA. Rashidi M, et al. Among authors: jamshidi h. J Cell Physiol. 2018 Nov;233(11):8908-8918. doi: 10.1002/jcp.26814. Epub 2018 May 24. J Cell Physiol. 2018. PMID: 29797576

4

National and sub-national prevalence, trend, and burden of metabolic risk factors (MRFs) in Iran: 1990 - 2013, study protocol.

Peykari N, Sepanlou SG, Djalalinia S, Kasaeian A, Parsaeian M, Ahmadvand A, Koohpayehzadeh J, Damari B, Jamshidi HR, Larijani B, Farzadfar F. Peykari N, et al. Arch Iran Med. 2014 Jan;17(1):54-61. Arch Iran Med. 2014. PMID: 24444064

5

The Most Prevalent Causes of Deaths, DALYs, and Geriatric Syndromes in Iranian Elderly People Between 1990 and 2010: findings from the Global Burden of Disease study 2010.

Namazi Shabestari A, Saeedi Moghaddam S, Sharifi F, Fadayevatan R, Nabavizadeh F, Delavari A, Jamshidi HR, Naderimagham S. Namazi Shabestari A, et al. Arch Iran Med. 2015 Aug;18(8):462-79. Arch Iran Med. 2015. PMID: 26265514

6

Burden of Cancers in Iran from 1990 to 2010: findings from the Global Burden of Disease study 2010.

Modirian M, Rahimzadeh S, Cheraghi Z, Saeedi Moghaddam S, Rezaei N, Tohidinik HR, Kasaeian A, Jamshidi HR, Ghobadi R, Kompani F. Modirian M, et al. Arch Iran Med. 2015 Oct;18(10):629-37. Arch Iran Med. 2015. PMID: 26443246

7

Hashemi-Meshkini A, Kebriaeezadeh A, Jamshidi H, Akbari-Sari A, Rezaei-Darzi E, Mehdipour P, Nikfar S, Farzadfar F. Hashemi-Meshkini A, et al. Among authors: jamshidi h. Arch Iran Med. 2016 Feb;19(2):116-22. Arch Iran Med. 2016. PMID: 26838082

8

Scientometric Study on Non-communicable Diseases in Iran: A Review Article.

Peykari N, Hashemi H, Asghari G, Ayazi M, Janbabaei G, Malekzadeh R, Raeisi A, Sadrolsadat A, Asadi-Lari M, Farshad A, Farzadfar F, Ghanei M, Haghdoost AA, Heshmat R, Jamshidi H, Ostovar A, Takian A, Larijani B. Peykari N, et al. Among authors: jamshidi h. Iran J Public Health. 2018 Jul;47(7):936-943. Iran J Public Health. 2018. PMID: 30181990 Free PMC article. Review.

9

NASBOD 2013: design, definitions, and metrics.

Farzadfar F, Delavari A, Malekzadeh R, Mesdaghinia A, Jamshidi HR, Sayyari A, Larijani B. Farzadfar F, et al. Arch Iran Med. 2014 Jan;17(1):7-15. Arch Iran Med. 2014. PMID: 24444059

10

National and sub-national trend and burden of injuries in Iran, 1990 - 2013: a study protocol.

Jamshidbeygi E, Rastad H, Qorbani M, Saadat S, Sepidarkish M, Asayesh H, Sepanlou SG, Shokraneh F, Najafi F, Khoramdad M, Maghsodi A, Farzadfar F, Jamshidi HR, Moradi-Lakeh M, Farzadfar F. Jamshidbeygi E, et al. Among authors: jamshidi hr. Arch Iran Med. 2014 Mar;17(3):138-45. Arch Iran Med. 2014. PMID: 24621356 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page